Dr Evan Lipson talks to ecancer about his Relativity-047 study which is in a global phase III trial comparing Relatlimab (RELA) + Nivolumab (NIVO) vs NIVO alone in patients with previously untreated, unresectable, or metastatic melanoma.
He begins by explaining that drugs that target immune checkpoints have dramatically improved survival rates for patients with a wide variety of cancers, including melanoma. In order to build on this and build novel combination regimens that are both safe and effective they decided to combine RELA + NIVO, as both drugs unleash an attack by immune T-cells against cancer.
He then goes onto say that the 2 drugs combined were in a fixed-dose combination (FDC) meaning that RELA + NIVO together were prepared in the same medication vial and were administered as a single intravenous infusion. This was done to reduce preparation and infusion time and to minimise the risk of administration errors.
Dr Lipson concludes by explaining that the combination demonstrated a manageable safety profile which saw a lower rate of serious toxicities that were related to therapy relative to other checkpoint inhibitor combinations.
Read more about the study here.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.